Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Sep;75(9):1255-9.
doi: 10.1136/jnnp.2003.027557.

Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up

Affiliations
Clinical Trial

Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up

B Ford et al. J Neurol Neurosurg Psychiatry. 2004 Sep.

Abstract

Objective: To measure the effect of deep brain stimulation (DBS) of the subthalamic nucleus in patients with advanced Parkinson's disease.

Design: Open label follow up using blinded ratings of videotaped neurological examinations.

Patients: 30 patients with advanced Parkinson's disease (19 male, 11 female; mean age 58.8 years; mean disease duration 12.8 years), complicated by intractable wearing off motor fluctuations and dopaminergic dyskinesias.

Main outcome measures: Unified Parkinson's disease rating scale (UPDRS), part III (motor), score at one year, from blinded reviews of videotaped neurological examinations. Secondary outcomes included the other UPDRS subscales, Hoehn and Yahr scale, activities of daily living (ADL) scale, mini-mental state examination (MMSE), estimates of motor fluctuations and dyskinesia severity, drug intake, and patient satisfaction questionnaire.

Results: Subthalamic nucleus stimulation was associated with a 29.5% reduction in motor scores at one year (p<0.0001). The only important predictors of improvement in UPDRS part III motor scores were the baseline response to dopaminergic drugs (p = 0.015) and the presence of tremor (p = 0.027). Hoehn and Yahr scores and ADL scores in the "on" and "off" states did not change, nor did the mean MMSE score. Weight gain occurred in the year after surgery, from (mean) 75.8 kg to 78.5 kg (p = 0.028). Duration of daily wearing off episodes was reduced by 69%. Dyskinesia severity was reduced by 60%. Drug requirements (in levodopa equivalents) declined by 30%.

Conclusions: The 30% improvement in UPDRS motor scores was a more modest result than previously reported. DBS did not improve functional capacity independent of drug use. Its chief benefits were reduction in wearing off duration and dyskinesia severity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arch Neurol. 2000 Jul;57(7):983-8 - PubMed
    1. Neurology. 1998 Sep;51(3):850-5 - PubMed
    1. N Engl J Med. 2001 Mar 8;344(10):710-9 - PubMed
    1. Neurology. 2001 Feb 27;56(4):552-4 - PubMed
    1. Mov Disord. 2002 Jan;17(1):125-32 - PubMed

Publication types

MeSH terms

Substances